Back to Search
Start Over
Changes in Bone Mineral Density through 96 Weeks in Antiretroviral-Naïve HIV-1 Infected Patients Receiving Abacavir/Lamivudine and Raltegravir in the SHIELD Trial
- Source :
- World Journal of AIDS. :38-44
- Publication Year :
- 2014
- Publisher :
- Scientific Research Publishing, Inc., 2014.
-
Abstract
- Decreased bone mineral density (BMD) and osteoporotic fractures are areas of increasing concern among HIV-infected persons. Particular concern is the rapid decline in BMD after initiation of antiretroviral treatment (ART). This report describes DEXA-assessed changes in BMD and body fat in a study of fifteen antiretroviral-na?ve adults initiating abacavir/lamivudine and raltegravir for 96 weeks. Median percent changes from baseline at weeks 48 and 96 in BMD were 0.29% and -0.11% (spine); -1.25% and -1.75% (left hip). Median percent changes from baseline in fat from baseline were -0.82% and -3.04% (trunk); 2.12% and 2.01% (limb). In this pilot study, ABC/3TC + RAL treatment had limited impact on BMD and body fat.
- Subjects :
- musculoskeletal diseases
Bone mineral
medicine.medical_specialty
business.industry
Human immunodeficiency virus (HIV)
Lamivudine
Abacavir/Lamivudine
musculoskeletal system
Raltegravir
medicine.disease_cause
Trunk
Surgery
Abacavir
Internal medicine
Antiretroviral naive
medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 21608822 and 21608814
- Database :
- OpenAIRE
- Journal :
- World Journal of AIDS
- Accession number :
- edsair.doi...........029a39e0bf7a67bee8755a60b78f6cc1